When cancer has spread or has stopped responding to other treatments, it helps to know that there are options designed to work more precisely. Lutetium-177 (Lu177) Octreotate Therapy is a targeted treatment for neuroendocrine cancers. It carries a radioactive substance directly to cancer cells, aiming to shrink tumours and keep the disease under control while sparing as much healthy tissue as possible.
Lu177 Octreotate Therapy is a form of targeted radionuclide therapy for patients with neuroendocrine cancers. It is ideal for patients with metastatic neuroendocrine cancer, meaning cancer that has spread, whose tumours show high tracer uptake on a Gallium-68 Octreotide PET/CT scan.
Neuroendocrine tumours develop from specialised hormone-producing cells found throughout the body, most commonly in the digestive tract, pancreas, and lungs. Many of these tumour cells have large numbers of proteins called somatostatin receptors on their surface. This feature is what makes the treatment possible.
The therapy is often described as a “magic bullet” form of cancer treatment, because carrier agents deliver tumour-destroying radioactive material directly to the targeted cancer tissue. The aim is to shrink the tumour and stabilise the disease. Patients whose bodies have not responded to other therapies or treatments may be referred for this therapy.
The treatment combines two parts. Octreotate is a molecule designed to attach to somatostatin receptors, which is why it homes in on neuroendocrine tumour cells. It is linked to Lutetium-177, a radioactive substance that releases a small, concentrated dose of radiation that travels only a very short distance. Once the combined medicine attaches to the tumour cells, the radiation damages them from within, while having less effect on the surrounding healthy tissue.
This is why the Gallium-68 Octreotide PET/CT scan is done beforehand. It shows whether your tumours take up the tracer strongly, which indicates that they are likely to take up the treatment in the same way. Lutetium-177 also gives off a small amount of imaging signal, which allows a scan the day after treatment to confirm where the medicine has gone.
Your doctor may recommend Lu177 Octreotate Therapy if you have a neuroendocrine cancer that has spread or cannot be removed by surgery, and your scan shows high tracer uptake in your tumours. It may be considered when other treatments have not worked well enough, or as part of a wider treatment plan decided together with your oncologist.
Before recommending the treatment, your Nuclear Medicine Physician will review your scans, blood tests, general health, and kidney and bone marrow function. Not everyone is suitable, and the therapy cannot be given during pregnancy or breastfeeding. Your doctor will talk you through all of your options.
A little preparation helps your treatment day to go smoothly. Before your first session, you will have a consultation with a Nuclear Medicine Physician, who will explain the treatment, the schedule, and the possible risks and benefits, and will answer your questions. Language interpretation services are available if you need them.
Each therapy cycle takes place as an outpatient appointment at the Nuclear Medicine Suite. Here is what usually happens:
Over the next few days, the radioactive medicine that has not attached to tumour cells will decay quickly and leave your body, mainly through your urine. You can resume normal activities after the post-infusion full-body scan.
As with any treatment, there are potential risks and side effects. The short-term effects that may follow the therapy include nausea and headache. Vomiting may also occur, although on rare occasions. Pre-medications are given to reduce the likelihood of these side effects.
Some people also feel tired for a few days after treatment. Because the medicine can temporarily affect the bone marrow, which makes blood cells, and is handled by the kidneys, your doctor will arrange regular blood tests during your course of treatment to monitor your blood counts and kidney function. Your care team will talk you through what to watch for.
Lu177 Octreotate Therapy is usually given as a course of several treatment cycles, with a gap of several weeks between them, rather than as a single session. Your doctor will plan how many cycles you need and when, based on your condition and how you respond. Between cycles, you will have regular reviews and blood tests, and scans will be used to assess how well the treatment is working. Your Nuclear Medicine Physician will keep in close contact with your oncologist and the rest of your care team so that your treatment is well coordinated.
Should you feel unwell after the procedure, contact your doctor immediately or call our 24-HR Medical Urgency Clinic at (65) 6705 2999.